BEAM logo

Beam Therapeutics Inc.

BEAM
Healthcare|Biotechnology|US
$26.41
+0.54 (+2.09%)
Tangible Book / Share
$9.10
Cash / Share
$9.97

Financials

Financial Snapshot

Market Cap
$2.73B
Enterprise Value
$2.76B
Revenue (TTM)
$146.6M
Net Income (TTM)
-$107.1M
Cash & Investments
$1.04B
Net Cash
$800.0M
Free Cash Flow (TTM)
-$398.2M
Operating CF (TTM)
-$388.6M
Debt/Equity
0.26

Cash Runway & Burn Rate

Cash on Hand
$1.04B
Quarterly Burn
$97.2M
Monthly Burn
$32.4M
Est. Runway
~10.7 quarters
MetricTrend201720182019202020212022202320242025TTM
Cash & Investments
$1.9M$146.4M$91.8M$299.7M$965.6M$1.08B$1.19B$850.7M$1.25B$1.04B
Operating Cash Flow
-$2.7M-$20.3M-$72.0M-$95.7M-$66.3M$22.5M-$149.2M-$347.2M-$345.1M-$388.6M
Free Cash Flow
-$3.1M-$33.4M-$84.5M-$112.1M-$113.1M-$26.4M-$182.9M-$356.2M-$360.0M-$398.2M
Capital Expenditure
-$346.0K-$13.1M-$12.5M-$16.4M-$46.8M-$49.0M-$33.7M-$8.9M-$14.9M-$9.6M
Financing Cash Flow
$5.0M$179.7M$41.3M$322.3M$756.1M$111.6M$276.4M$7.7M$478.0M$108.3M

R&D Spending

R&D (TTM)
$409.0M
R&D Intensity
278.9%
R&D Growth vs Prior
-0.1%
MetricTrend201720182019202020212022202320242025TTM
Revenue
$0.00$0.00$18.0K$24.0K$51.8M$60.9M$377.7M$63.5M$139.7M$146.6M
R&D Expense
$5.9M$33.9M$54.6M$103.2M$387.1M$311.6M$437.4M$367.6M$409.6M$409.0M
R&D % of Revenue
——303438.9%429912.5%746.6%511.5%115.8%578.7%293.1%278.9%
SG&A
$2.2M$11.9M$20.6M$29.6M$57.2M$87.8M$116.8M$111.5M$113.8M$130.2M

Income Statement

MetricTrend201720182019202020212022202320242025TTM
Revenue
$0.00$0.00$18.0K$24.0K$51.8M$60.9M$377.7M$63.5M$139.7M$146.6M
Cost of Revenue
$0.00$33.9M$54.6M$103.2M$232.1M$311.6M$0.00$367.6M$22.3M$0.00
Gross Profit
$0.00-$33.9M-$54.6M-$103.2M-$180.3M-$250.7M$377.7M-$304.0M$117.4M$146.6M
R&D
$5.9M$33.9M$54.6M$103.2M$387.1M$311.6M$437.4M$367.6M$409.6M$409.0M
SG&A
$2.2M$11.9M$20.6M$29.6M$57.2M$87.8M$116.8M$111.5M$113.8M$130.2M
Operating Income
-$8.6M-$45.7M-$75.2M-$132.8M-$392.5M-$338.5M-$176.5M-$415.6M-$383.7M-$392.5M
Interest Expense
$0.00$0.00$187.0K$0.00$0.00$0.00$0.00$0.00$43.7M$0.00
Pretax Income
-$8.7M-$116.7M-$78.3M-$194.6M-$370.6M-$285.7M-$131.2M-$376.7M-$80.0M-$107.1M
Net Income
-$8.7M-$115.3M-$78.3M-$194.6M-$370.6M-$289.1M-$132.5M-$376.7M-$80.0M-$107.1M
EPS (Diluted)
-0.62-3.28-1.53-5.49-5.77-4.13-1.72-4.58-0.81-1.04
EBITDA
-$8.6M-$45.1M-$71.7M-$128.0M-$230.1M-$271.5M-$111.1M-$354.8M-$14.0M-$85.0M
Shares Out. (M)
12.9535.1451.3446.7364.2370.0277.1582.3198.91104.70

Balance Sheet

MetricTrend201720182019202020212022202320242025TTM
Cash & Equivalents
$1.9M$146.4M$37.2M$162.2M$560.0M$232.8M$435.9M$282.0M$294.9M$213.3M
Short-Term Investments
$0.00$0.00$54.6M$137.5M$405.7M$845.4M$754.0M$568.8M$950.3M$830.6M
Total Current Assets
$2.0M$148.3M$94.5M$308.3M$1.27B$1.09B$1.21B$878.1M$1.27B$1.07B
Total Assets
$2.4M$167.0M$156.1M$451.7M$1.47B$1.34B$1.46B$1.10B$1.48B$1.27B
Total Current Liabilities
$6.6M$25.6M$29.1M$102.3M$213.4M$223.6M$205.6M$182.1M$96.9M$82.1M
Long-Term Debt
$0.00$0.00$4.4M$5.3M$3.0M$0.00$0.00$0.00$139.8M$100.4M
Total Liabilities
$6.6M$33.0M$55.2M$206.1M$647.7M$608.2M$478.4M$370.3M$242.8M$316.4M
Stockholders' Equity
-$4.2M$134.0M$100.9M$245.6M$826.7M$733.5M$981.3M$733.5M$1.24B$952.7M
Retained Earnings
-$9.5M-$124.7M-$203.0M-$397.6M-$768.3M-$1.06B-$1.19B-$1.57B-$1.64B-$1.99B

Cash Flow Statement

MetricTrend201720182019202020212022202320242025TTM
Operating Cash Flow
-$2.7M-$20.3M-$72.0M-$95.7M-$66.3M$22.5M-$149.2M-$347.2M-$345.1M-$388.6M
Capital Expenditure
-$346.0K-$13.1M-$12.5M-$16.4M-$46.8M-$49.0M-$33.7M-$8.9M-$14.9M-$9.6M
Free Cash Flow
-$3.1M-$33.4M-$84.5M-$112.1M-$113.1M-$26.4M-$182.9M-$356.2M-$360.0M-$398.2M
Investing Cash Flow
-$346.0K-$13.4M-$66.7M-$100.1M-$294.1M-$461.3M$71.8M$185.0M-$121.4M$225.7M
Financing Cash Flow
$5.0M$179.7M$41.3M$322.3M$756.1M$111.6M$276.4M$7.7M$478.0M$108.3M
Issuance of Stock
$5.0M$179.7M$0.00$319.5M$757.4M$108.3M$270.2M$8.2M$478.0M$15.3M
Repurchase of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Net Debt Issuance
$0.00$0.00$5.7M$1.7M-$2.1M-$2.3M-$2.3M-$485.0K$0.00$94.7M
Stock Based Comp.
$198.0K$7.0M$7.0M$15.4M$43.6M$84.3M$98.6M$120.7M$94.2M-$16.9M
Net Change in Cash
$1.9M$146.0M-$97.4M$126.5M$395.7M-$327.2M$199.1M-$154.5M$11.5M-$54.7M

Dilution Tracker

Shares outstanding grew 111.6% over 5 years — significant dilution
Shares Outstanding
103M
5-Year Share Growth
+111.6%
Stock Issuance (TTM)
$15.3M
MetricTrend201720182019202020212022202320242025TTM
Shares Out. (M)
12.9535.1451.3446.7364.2370.0277.1582.3198.91104.70
Change vs Prior %
—171.3%46.1%-9.0%37.4%9.0%10.2%6.7%20.2%5.9%
Stock Issuance
$5.0M$179.7M$0.00$319.5M$757.4M$108.3M$270.2M$8.2M$478.0M$15.3M
Stock Repurchase
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Stock Based Comp.
$198.0K$7.0M$7.0M$15.4M$43.6M$84.3M$98.6M$120.7M$94.2M-$16.9M

Margins & Profitability

MetricTrend201720182019202020212022202320242025TTM
Gross Margin %
——-303338.9%-429812.5%-347.8%-411.5%100.0%-478.7%84.0%100.0%
Operating Margin %
——-417522.2%-553166.7%-757.0%-555.6%-46.7%-654.3%-274.6%-267.7%
Net Margin %
——-435144.4%-810800.0%-714.9%-474.5%-35.1%-593.1%-57.2%-73.0%
EBITDA Margin %
——-398061.1%-533437.5%-443.8%-445.7%-29.4%-558.5%-10.0%-57.9%
FCF Margin %
——-469561.1%-467075.0%-218.1%-43.4%-48.4%-560.8%-257.7%-271.6%
ROE %
208.7%-86.0%-77.6%-79.2%-44.8%-39.4%-13.5%-51.4%-6.5%-9.7%
ROA %
-363.4%-69.0%-50.2%-43.1%-25.1%-21.5%-9.1%-34.1%-5.4%-8.4%
ROIC %
272.6%-32.3%-56.7%-37.3%-30.9%-30.0%-13.9%-44.4%-27.4%-32.6%
R&D / Revenue %
——303438.9%429912.5%746.6%511.5%115.8%578.7%293.1%278.9%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend201720182019202020212022202320242025
Revenue
0.0%0.0%0.0%33.3%215916.7%17.5%520.0%-83.2%120.0%
Gross Profit
0.0%0.0%-61.2%-88.9%-74.8%-39.0%250.7%-180.5%138.6%
Operating Income
0.0%-432.1%-64.3%-76.7%-195.6%13.8%47.9%-135.5%7.7%
Net Income
0.0%-1220.3%32.0%-148.4%-90.5%22.0%54.2%-184.3%78.8%
EPS (Diluted)
0.0%-429.0%53.4%-258.8%-5.1%28.4%58.4%-166.3%82.3%
Operating Cash Flow
0.0%-649.8%-254.7%-33.0%30.8%134.0%-762.3%-132.7%0.6%
Free Cash Flow
0.0%-994.7%-152.9%-32.6%-0.9%76.6%-592.3%-94.7%-1.1%
R&D Expense
0.0%478.1%61.2%88.9%275.2%-19.5%40.4%-16.0%11.4%
SG&A Expense
0.0%438.3%73.2%44.0%93.3%53.4%33.0%-4.5%2.1%
Total Assets
0.0%6853.0%-6.5%189.4%226.4%-9.0%8.8%-24.4%34.2%
Book Value / Share
0.0%1281.1%-48.5%167.2%145.0%-18.6%21.4%-29.9%40.5%
Debt
0.0%-100.0%0.0%244.6%37.2%21.2%-3.5%-6.5%82.1%
Diluted Shares
0.0%171.3%46.1%-9.0%37.4%9.0%10.2%6.7%20.2%

Valuation

P/E (TTM)At Loss
P/S18.60
10Y Low / Med / High5.56 / 44.95 / 158970.84
P/B2.90
10Y Low / Med / High2.14 / 4.92 / 15.54
EV/EBITDAAt Loss
EV/Revenue18.81
10Y Low / Med / High4.86 / 44.07 / 156698.88
P/FCFAt Loss

Intrinsic Value Models (per share)

Tangible Book / Share
$9.10
Net Current Assets / Share
$7.27
Graham Net-Net
$6.95
Cash / Share
$9.97
MetricTrend201720182019202020212022202320242025TTM
P/E Ratio
-30.24-5.72-12.25-14.87-13.81-9.47-15.83-5.41-34.22-26.41
P/S Ratio
0.000.0053478.86158970.8498.7344.955.5632.1419.6218.60
P/B Ratio
-58.064.929.5415.546.193.732.142.782.212.90
EV/EBITDA
-28.18-11.36-13.35-29.38-20.46-9.89-16.53-5.41-196.25-32.46
EV/Revenue
0.000.0053146.47156698.8890.7744.074.8630.2419.6118.81

Analyst Estimates & Quality

Altman Z-Score
3.74
Safe
Piotroski F-Score
2
Weak

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$39.1M$38.8M$80.6M
Net Income-$454.7M-$545.9M-$551.9M
EPS$-4.61$-5.10$-4.74
# Analysts (EPS)111111

Dividends

Frequency
Quarterly

Recent Payments

Ex-DatePay DateAmountFrequency
Nov 4, 2013Dec 2, 2013$0.23Quarterly
Aug 12, 2013Sep 3, 2013$0.23Quarterly
May 6, 2013Jun 3, 2013$0.23Quarterly
Feb 4, 2013Mar 1, 2013$0.23Quarterly
Feb 6, 2012Mar 1, 2012$0.21Quarterly